Alerta

Methods for Providing Rapid Relief of Motor Fluctuations in a Parkinson's Disease Patient

Resumen de: US20260115160A1

The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.

GENE CORRECTION INDUCED NEURAL STEM CELLS USING HUNTINGTIN GENE-SPECIFIC GUIDE RNA, AND CELL THERAPEUTIC AGENT USING THE SAME

Resumen de: US20260115318A1

The present invention relates to: a gene editing composition comprising a guide RNA for editing mutated CAG repeat sequences of neural stem cells (ciNSCs) induced from somatic cells of a Huntington's disease patient; the edited ciNSCs; and a cell therapeutic agent for Huntington's disease, comprising same, wherein, in the edited ciNSCs, Huntington gene mutations are removed by the guide RNA of the present invention, and thus treatment for Huntington's disease and neuronal proliferation can be improved.

HTT REPRESSORS AND USES THEREOF

Resumen de: US20260116932A1

Disclosed herein are improved methods and compositions for diagnosing, preventing and/or treating Huntington's Disease. Among other things, provided herein is a gene therapy construct encoding a non-naturally occurring codon-optimized transcription factor (ZFP-TF) comprising a zinc-finger protein (ZFP) sequence and a sequence encoding a transcriptional repression domain, wherein the ZFP-TF expression is driven by a phosphoglycerate kinase 1 (PGK), ubiquitin C (UBC), an EFS, or an EF1alpha promoter.

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

Resumen de: US20260116878A1

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS

Resumen de: WO2024261329A1

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y1 is a 9- or 10-membered bicyclic heteroaryl, Y2 is a 5- or 6-membered heteroaryl or 6-membered aryl, L is a linker, Z1' is selected from -NR23' R24' and -(C3-C7) heterocyclo alkyl comprising at least one nitrogen atom, and R23' and R24' may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies, cardiovascular diseases, or metabolic or hormonal disorders.

ANTI-TDP-43 ANTIBODIES AND USES THEREOF

Resumen de: AU2024342582A1

The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).

THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE

Resumen de: US20260108494A1

0000 The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) wherein each symbol is as defined in the description or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same. 0000

TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM

Resumen de: AU2024357688A1

This invention relates to the treatment of a neuropsychiatric disorder, such as schizophrenia or Parkinson's disease, by administration (for example, transdermally) of tilivapram, zatolmilast, roflumilast, or a pharmaceutically acceptable salt thereof.

ALZHEIMER-TYPE DEMENTIA SUPPRESSANT, AND METHOD FOR PRODUCING SAME

Resumen de: US20260108572A1

0000 The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.

BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS FOR ALLEVIATING PARKINSON'S DISEASE AND USE THEREOF

Resumen de: US20260108568A1

0000 Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No. 24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.

VACCINES AND ANTIBODIES FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS AND INFLAMMATION RELATED HEALTH CONDITIONS

Resumen de: WO2026085054A1

The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and/or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and/or limbic predominant age-related TDP-43 encephalopathy (LATE).

ANTI-BETA AMYLOID ANTIBODIES AND USES THEREOF

Resumen de: WO2026082154A1

Deposition of N-terminally truncated and pyroglutamate-modified Abeta peptides (AβpE3) play an important role in the aggregation of the amyloid-β (Aβ) protein in the brain. The N-terminally truncated and pyroglutamate-modified Abeta peptides, therefore, can be a suitable target for the prevention and treatment of Alzheimer's Disease (AD). Disclosed herein are antibodies and fragments having excellent specificity to N-terminally truncated and pyroglutamate-modified Abeta peptides, as well as uses of these antibodies and fragments for the prevention and treatment of AD.

COMPOSITION CONTAINING BRAIN PROTEIN HYDROLYSATE, PREPARATION METHOD, AND USE

Resumen de: WO2026081146A1

A composition containing a brain protein hydrolysate, a preparation method, and a use. The composition comprises the following raw materials: porcine brain protein hydrolysate, deer brain protein hydrolysate, bovine collagen peptide powder, Gastrodia elata powder, sea buckthorn powder, hawthorn powder, chicken gizzard membrane powder, vitamin C, vitamin B1, vitamin B3, vitamin B5, vitamin B6, and vitamin B12. The composition has anti-inflammatory and antioxidant effects, and can also be used for preparing a medicament for preventing Alzheimer's disease.

MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA FORMULATIONS AND METHODS OF USE THEREOF

Resumen de: WO2026085233A1

The disclosure relates to formulations of double stranded ribonucleic acid (dsRNAi) agents targeting a MAPT gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated neurodegenerative disease or disorder, e.g., Alzheimer's disease, FTD, PSP, or other tauopathy, using such dsRNAi agent formulations.

HIGH-DOSE GAD GENE THERAPY FOR TREATING PARKINSON'S DISEASE

Resumen de: WO2026085129A1

Provided herein are compositions and methods for treating or preventing neurodegenerative disease and for treating or preventing symptoms associated with neurodegenerative disease, including Parkinson's disease. For example, provided are methods of treating a patient with Parkinson's disease, the method comprising administering to the patient vectors comprising a nucleic acid encoding glutamic acid decarboxylase (GAD).

TREATMENT OF PATHOLOGIES ASSOCIATED WITH DOWN SYNDROME WITH ANTI-FSH ANTIBODIES

Resumen de: WO2026085535A2

Disclosed is a method for treating for treating pathologies associated with Down syndrome (e.g., symptoms of Alzheimer's disease and metabolic abnormalities), preventing the onset of pathologies associated with Down syndrome in patients with Down syndrome, reducing cognitive or functional decline, or reducing symptom load in a subject having Down Syndrome, in need or at risk thereof, comprising administering to said subject a therapeutically effective amount of an anti-Follicle Stimulating Hormone (FSH) antibody, or an antigen-binding portion thereof.

FUSED HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Resumen de: WO2026082004A1

The present invention relates to a fused heteroaryl derivative, a preparation method therefor, and an application thereof. The fused heteroaryl derivative can be used in a sodium channel inhibitor, and/or in a GABA receptor agonist, or in treating neuropsychiatric disorders such as epilepsy, Parkinson's, schizophrenia, or depression.

KRÄUTERLÖSUNG, DIE RUTA GRAVEOLENS UND SAXIFRAGA ENTHÄLT, UND VERFAHREN ZU IHRER HERSTELLUNG

Resumen de: DE102024130715A1

Die vorliegende Offenbarung bezieht sich auf eine pflanzliche Mundspüllösung, die Ruta graveolens und Saxifraga enthält und speziell zur Vorbeugung von neurologischen Erkrankungen wie Parkinson, Alzheimer, Lähmungen und Nervenschäden entwickelt wurde. Verfahren zur Herstellung der pflanzlichen Mundspüllösung durch Einweichen einer fein gemahlenen Mischung aus Ruta graveolens und Saxifraga in Alkohol. Die resultierende Lösung wird als Mundspülung verabreicht und zum Spülen und Gurgeln verwendet. Die Erfindung bietet eine wirksame, natürliche therapeutische Alternative zur Behandlung neurodegenerativer Erkrankungen, zur Förderung des Neuroschutzes und zur möglichen Unterstützung der Regeneration geschädigter Nervenzellen.

USE OF NLRP3 INHIBITOR FOR TREATING PARKINSON'S DISEASE OR PARKINSONISM

Resumen de: WO2026082108A1

The present invention relates to use of an NLRP3 inhibitor for treating Parkinson's disease or Parkinsonism. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating Parkinson's disease or Parkinsonism, wherein each substituent is as defined in the specification.

PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY AMINES AND THEIR USE AS INTERMEDIATES

Resumen de: WO2024260959A1

The present invention relates to an improved process for preparing optically active secondary amines, or a pharmaceutically or veterinary acceptable salt thereof, in high yield and high purity involving (2-naphthoyl)-L-proline as chiral resolving agent. The invention also relates to the use of (2-naphthoyl)-L-proline as chiral resolving agent of secondary amines, preferably of amine compounds of formula (I), wherein R1 is H, C1- C4 alkyl, preferably R1 is methyl; and R2 is C1-C4 alkyl, preferably R2 is n-propyl and the use of the obtained optically amine compounds of formula (IV) for the preparation of rotigotine.

GENE THERAPY VECTOR FOR TREATING PARKINSON'S DISEASE AND USE THEREOF

Resumen de: EP4729620A1

Provided are a gene therapy vector for treating Parkinson's disease and a use thereof. Specifically, provided is an adeno-associated virus (AAV) vector for treating Parkinson's disease, which can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC) to promote dopamine synthesis. Also provided are an AAV virus particle containing the AAV vector, a composition containing the AAV vector or the AAV virus particle, and uses of the AAV vector, the AAV virus particle and the composition in the preparation of drugs for preventing or treating Parkinson's disease.

Compounds

Resumen de: GB2701173A

A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is independently selected from: halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -O-C1-C6 alkyl and -SO2-C1-C6 alkyl; R2 is independently selected from: H, halo, and -CN; R3 is selected from: halo, and -O-C1-C6 alkyl; R4 is independently selected from: halo, -CN, C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, and -O-C1-C6 alkyl-C3-C6 cycloalkyl; wherein said C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, and -O-C1-C6 alkyl-C3-C6 cycloalkyl, are each independently optionally substituted with from 1 to 6 groups selected from: deuterium, -CN, halo, -O-C1-C3 alkyl, and -O-C1-C3 haloalkyl; R5 is selected from: H, halo, and -O-C1-C6 alkyl; X1 is CR6; and R6 is independently selected from: H, halo, C1-C6 alkyl, C1-C6 haloalkyl, -O-C1-C6 alkyl, and -O-C1-C6 haloalkyl. The compounds are GPR17 modulators. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases and conditions associated with GPR17, including multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). Figure formula (I)

SIRNA INHIBITING EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP) GENE, DRUG, AND USE

Resumen de: AU2024354107A1

Provided are an siRNA inhibiting the expression of an amyloid precursor protein (APP) gene in a human cell, a polypeptide-oligonucleotide drug, and a use. The siRNA has good APP expression inhibitory activity, and a suitable modification is made to the siRNA to improve the silencing capability against a target and reduce off-target activity. The siRNA and a conjugate thereof are expected to be applied for clinically preventing and treating an APP target-related disease such as cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

THERAPEUTIC TARGETING OF FIBRONECTIN 1 FOR MITIGATING ALZHEIMER'S DISEASE PATHOLOGY

Resumen de: WO2026080717A1

Methods and compositions for treating or reducing the development of neurodegenerative diseases.

MUSE CELL-DERIVED PROTEIN COMPLEX, PREPARATION METHOD THEREFOR, AND USE THEREOF

Nº publicación: WO2026077393A1 16/04/2026

Solicitante:

DARWIN BIOTECHNOLOGY HUBEI CO LTD [CN]
\u8FBE\u5C14\u6587\u751F\u7269\u79D1\u6280\uFF08\u6E56\u5317\uFF09\u6709\u9650\u516C\u53F8

Resumen de: WO2026077393A1

The present invention belongs to the field of biopharmaceuticals. Disclosed are a Muse cell-derived protein complex, a preparation method therefor, and use thereof. The composition of the protein complex is: a stem cell lysate of Muse cells after being cultured in a stress environment for a predetermined time, or a protein complex obtained by separating and purifying the stem cell lysate. The protein complex has a good cell damage repair effect, especially a strong ability to repair nerve cell damage, and is expected to be used for treating neurodegenerative diseases, cerebral stroke, cerebrovascular disease, arthritis, enteritis, recovery after trauma, autism, depression, and pulmonary fibrosis. In particular, the neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and different types of spinocerebellar ataxia (SCA).